Arcus Biosciences, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for RCUS, updated each market day.
RCUS AI Sentiment
AI sees no strong directional signal for Arcus Biosciences, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Arcus Biosciences, Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Sector
Exchange
Market Cap
$2,918,135,801
Cap Tier
Employees
601
Headquarters
HAYWARD, CA
Listed Since
March 15, 2018
Website
RCUS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RCUS Volatility
Arcus Biosciences, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
